Browse studies

Find your next paid study

3,226 recruiting studies matching your filters

A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 Monotherapy and in Combination With Other Agents in Adult Patients With Advanced Solid Tumors With KRAS Alteration

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants wi…

Advanced Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Jacobio Pharmaceuticals Co., Ltd.NCT06973564

Phase 1

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating p…

Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8+1 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06811116

Phase 2

Intravesical Nadofaragene Firadenovec With Neoadjuvant Chemotherapy and Durvalumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)

This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with gemcitabine, cisplatin and durvalumab before (neoadjuvant) ra…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of WashingtonNCT07332351

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Rese…

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT02682667

Observational

Pilot Study to Assess Safety, Tolerability and Efficacy of Virtual Reality in Cancer Patients

This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer pati…

Adjustment DisorderAnxiety DisorderDepression+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT07221409

Phase 2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melan…

Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell Carcinoma+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05155033

Phase 2

A Double-Blind, Randomized, Multi-Center, Dose-Ranging, Phase 2 Study of the Efficacy and Safety of ALV-100 Versus Placebo for Maintenance of Weight Loss in Patients Previously Treated With Incretin-Based Therapies

A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reducti…

Overweight , ObesityAdults

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Alveus Therapeutics, Inc.NCT07837973

Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic …

Pancreatic Acinar Cell CarcinomaPancreatic Adenosquamous CarcinomaPancreatic Squamous Cell Carcinoma+4 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT04858334

Observational

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy (ACE)

The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemot…

Metastatic Bladder CancerPeripheral NeuropathyAdvanced Urothelial Cancer+3 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT07548476

The Molecular Basis of Inherited Reproductive Disorders

Background: \- During puberty, children begin to develop into adults. Problems with the hormones released during puberty can affect the reproductive system. S…

Genetic DisorderInfertilityHypogonadism+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Environmental Health Sciences (NIEHS)NCT01500447

Phase 2

Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works bet…

NSCLC (Advanced Non-small Cell Lung Cancer)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Multitude Therapeutics Inc.NCT07718737

Phase 1

A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)+2 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Alterome Therapeutics, Inc.NCT06835569